Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage

Oncotarget

Volumn 6, Issue 12, 2015, Pages 9970-9984

  Ko, Hyeonseok ^c   Jeong, Mi Hyeon ^a,b   Jeon, Hyelin ^a   Sung, Gi Jun ^a   So, Youngsin ^a   Kim, InKi ^a   Son, JaeKyoung ^a   Lee, Sang Wook ^a   Yoon, Ho Geun ^b   Choi, Kyung Chul ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Dankook University   (South Korea)

Author keywords

Apoptosis; Delphinidin; HDAC3; Prostate cancer; TRAIL

Indexed keywords

CASPASE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; DEATH RECEPTOR 5; DELPHINIDIN; HISTONE DEACETYLASE 3; INHIBITOR OF APOPTOSIS PROTEIN 2; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P21; PROTEIN P53; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; ANTHOCYANIN; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN INDUCTION; SENSITIZATION; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; DRUG EFFECTS; DRUG POTENTIATION; GENETIC TRANSFECTION; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANTHOCYANINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DRUG SYNERGISM; HISTONE DEACETYLASES; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 84929598250     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3667     Document Type: Article

References (74)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010; 60:277-300.
2. Hayat MJ, Howlader N, Reichman ME and Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. The oncologist. 2007; 12:20-37.
3. Long RJ, Roberts KP, Wilson MJ, Ercole CJ and Pryor JL. Prostate cancer: a clinical and basic science review. Journal of andrology. 1997; 18:15-20.
4. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology. 1999; 54(6A Suppl):30-35.
5. Pisters LL. The challenge of locally advanced prostate cancer. Seminars in oncology. 1999; 26(2):202-216.
6. Richie JP. Anti-androgens and other hormonal therapies for prostate cancer. Urology. 1999; 54(6A Suppl):15-18.
7. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature medicine. 1999; 5:157-163.
8. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science. 1997; 276:111-113.
9. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG and Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. The EMBO journal. 1997; 16:5386-5397.
10. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG and Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. The Journal of experimental medicine. 1997; 186:1165-1170.
11. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA and Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 1997; 7:813-820.
12. Bellail AC, Tse MC, Song JH, Phuphanich S, Olson JJ, Sun SY and Hao C. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. Journal of cellular and molecular medicine. 2010; 14:1303-1317.
13. Fernald K and Kurokawa M. Evading apoptosis in cancer. Trends in cell biology. 2013; 23:620-633.
14. Bhojani MS, Rossu BD and Rehemtulla A. TRAIL and anti-tumor responses. Cancer biology & therapy. 2003; 2(4 Suppl 1):S71-78.
15. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Molecular immunology. 2003; 39:615-647.
16. Reed JC, Doctor KS and Godzik A. The domains of apoptosis: a genomics perspective. Science's STKE : signal transduction knowledge environment. 2004; 2004:re9.
17. Bossy-Wetzel E and Green DR. Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. The Journal of biological chemistry. 1999; 274:17484-17490.
18. Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM, Alnemri ES, Fairman R and Shi Y. Mechanism of XIAP-mediated inhibition of caspase-9. Molecular cell. 2003; 11:519-527.
19. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD and El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer cell. 2007; 12:66-80.
20. Zhao J, Lu Y and Shen HM. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer letters. 2012; 314:8-23.
21. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J and Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature. 2008; 451:587-590.
22. Kim JE, Chen J and Lou Z. DBC1 is a negative regulator of SIRT1. Nature. 2008; 451(7178):583-586.
23. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S and Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC cancer. 2005; 5:54.
24. Dyer MJ, MacFarlane M and Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007; 25:4505-4506.
25. Morales JC, Ruiz-Magana MJ and Ruiz-Ruiz C. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition. Molecular immunology. 2007; 44:2587-2597.
26. Zhang Y and Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Molecular cancer research : MCR. 2008; 6:1861-1871.
27. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C and Liu X. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology. 2004; 39:1371-1381.
28. Shankar S and Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation:mechanisms and clinical implications. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2004; 7:139-156.
29. Shin EA, Sohn EJ, Won G, Choi JU, Jeong M, Kim B, Kim MJ and Kim SH. Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. Oncotarget. 2014; 5:5624-5636.
30. Bronikowska J, Szliszka E, Czuba ZP, Zwolinski D, Szmydki D and Krol W. The combination of TRAIL and isoflavones enhances apoptosis in cancer cells. Molecules. 2010; 15:2000-2015.
31. Shin SW and Park JW. Ursolic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Biochimica et biophysica acta. 2013; 1833:723-730.
32. Park SJ, Park SH, Kim JO, Kim JH, Park SJ, Hwang JJ, Jin DH, Jeong SY, Lee SJ, Kim JC, Kim I and Cho DH. Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the upregulation of Bax. Biochemical and biophysical research communications. 2012; 428:185-190.
33. Charette N, De Saeger C, Horsmans Y, Leclercq I and Starkel P. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivindependent mechanisms. Cell death & disease. 2013; 4:e471.
34. Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA, Lim JH, Kwon TK and Choi KS. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis. 2013; 34:1918-1928.
35. Lin T, Ding Z, Li N, Xu J, Luo G, Liu J and Shen J. 2-Tellurium-bridged beta-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NFkappaB suppression. Carcinogenesis. 2011; 32:154-167.
36. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA and Gautam SC. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Molecular cancer therapeutics. 2003; 2:95-103.
37. Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S and Mukhtar H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene. 2008; 27:2055-2063.
38. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM and Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. The Prostate. 2007; 67:1641-1653.
39. Ozoren N and El-Deiry WS. Cell surface Death Receptor signaling in normal and cancer cells. Seminars in cancer biology. 2003; 13:135-147.
40. Jung KJ, Min KJ, Bae JH and Kwon TK. Carnosic acid sensitized TRAIL-mediated apoptosis through downregulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells. Oncotarget. 2014.
41. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK. Histone deacetylases and cancer: causes and therapies. Nature reviews Cancer. 2001; 1:194-202.
42. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature reviews Drug discovery. 2002; 1:287-299.
43. Marks PA, Richon VM, Miller T and Kelly WK. Histone deacetylase inhibitors. Advances in cancer research. 2004; 91:137-168.
44. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S and Ragno R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Medicinal research reviews. 2005; 25:261-309.
45. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB. Histone deacetylases (HDACs):characterization of the classical HDAC family. The Biochemical journal. 2003; 370:737-749.
46. Blander G and Guarente L. The Sir2 family of protein deacetylases. Annual review of biochemistry. 2004; 73:417-435.
47. Li Z and Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. International journal of biological sciences. 2014; 10:757-770.
48. Inoue S, Mai A, Dyer MJ and Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis. Cancer research. 2006; 66:6785-6792.
49. Xia Y, Wang J, Liu TJ, Yung WK, Hunter T and Lu Z. c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Molecular cell. 2007; 25:219-232.
50. Panteleeva I, Rouaux C, Larmet Y, Boutillier S, Loeffler JP and Boutillier AL. HDAC-3 participates in the repression of e2f-dependent gene transcription in primary differentiated neurons. Annals of the New York Academy of Sciences. 2004; 1030:656-660.
51. Escaffit F, Vaute O, Chevillard-Briet M, Segui B, Takami Y, Nakayama T and Trouche D. Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Molecular and cellular biology. 2007; 27:554-567.
52. Hou DX, Fujii M, Terahara N and Yoshimoto M. Molecular Mechanisms Behind the Chemopreventive Effects of Anthocyanidins. Journal of biomedicine & biotechnology. 2004; 2004:321-325.
53. Wang LS and Stoner GD. Anthocyanins and their role in cancer prevention. Cancer letters. 2008; 269(2):281-290.
54. Thomasset S, Teller N, Cai H, Marko D, Berry DP, Steward WP and Gescher AJ. Do anthocyanins and anthocyanidins, cancer chemopreventive pigments in the diet, merit development as potential drugs? Cancer chemotherapy and pharmacology. 2009; 64:201-211.
55. Hafeez BB, Siddiqui IA, Asim M, Malik A, Afaq F, Adhami VM, Saleem M, Din M and Mukhtar H. A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling. Cancer research. 2008; 68:8564-8572.
56. Noda Y, Kaneyuki T, Mori A and Packer L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin. Journal of agricultural and food chemistry. 2002; 50:166-171.
57. Hou DX, Yanagita T, Uto T, Masuzaki S and Fujii M. Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: structure-activity relationship and molecular mechanisms involved. Biochemical pharmacology. 2005; 70:417-425.
58. Favot L, Martin S, Keravis T, Andriantsitohaina R and Lugnier C. Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on angiogenesis. Cardiovascular research. 2003; 59:479-487.
59. Azevedo L, Alves de Lima PL, Gomes JC, Stringheta PC, Ribeiro DA and Salvadori DM. Differential response related to genotoxicity between eggplant (Solanum melanogena) skin aqueous extract and its main purified anthocyanin (delphinidin) in vivo. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2007; 45:852-858.
60. Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V and Mukhtar H. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicology and applied pharmacology. 2008; 231:52-60.
61. Lazze MC, Savio M, Pizzala R, Cazzalini O, Perucca P, Scovassi AI, Stivala LA and Bianchi L. Anthocyanins induce cell cycle perturbations and apoptosis in different human cell lines. Carcinogenesis. 2004; 25:1427-1433.
62. Zhang Y, Vareed SK and Nair MG. Human tumor cell growth inhibition by nontoxic anthocyanidins, the pigments in fruits and vegetables. Life sciences. 2005; 76:1465-1472.
63. Bin Hafeez B, Asim M, Siddiqui IA, Adhami VM, Murtaza I and Mukhtar H. Delphinidin, a dietary anthocyanidin in pigmented fruits and vegetables: a new weapon to blunt prostate cancer growth. Cell cycle. 2008; 7:3320-3326.
64. Yun JM, Afaq F, Khan N and Mukhtar H. Delphinidin, an anthocyanidin in pigmented fruits and vegetables, induces apoptosis and cell cycle arrest in human colon cancer HCT116 cells. Molecular carcinogenesis. 2009; 48:260-270.
65. Kelley SK and Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Current opinion in pharmacology. 2004; 4:333-339.
66. Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY and El-Deiry WS. Mitomycin C potentiates TRAIL-induced apoptosis through p53- independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell cycle. 2012; 11:3312-3323.
67. Kim YJ, Choi WI, Ko H, So Y, Kang KS, Kim I, Kim K, Yoon HG, Kim TJ and Choi KC. Neobavaisoflavone sensitizes apoptosis via the inhibition of metastasis in TRAIL-resistant human glioma U373MG cells. Life sciences. 2014; 95:101-107.
68. Martinez-Paniagua MA, Baritaki S, Huerta-Yepez S, Ortiz-Navarrete VF, Gonzalez-Bonilla C, Bonavida B and Vega MI. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell cycle. 2011; 10:2792-2805.
69. Clohessy JG, Zhuang J, de Boer J, Gil-Gomez G and Brady HJ. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptormediated apoptosis. The Journal of biological chemistry. 2006; 281:5750-5759.
70. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J and Wong J. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. The EMBO journal. 2003; 22:1336-1346.
71. Liu F, Dowling M, Yang XJ and Kao GD. Caspasemediated specific cleavage of human histone deacetylase 4. The Journal of biological chemistry. 2004; 279:34537-34546.
72. Paroni G, Mizzau M, Henderson C, Del Sal G, Schneider C and Brancolini C. Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis. Molecular biology of the cell. 2004; 15:2804-2818.
73. Ko H, Kim S, Jin CH, Lee E, Ham S, Yook JI and Kim K. Protein kinase casein kinase 2-mediated upregulation of N-cadherin confers anoikis resistance on esophageal carcinoma cells. Molecular cancer research : MCR. 2012; 10:1032-1038.
74. Kim YJ, Choi WI, Jeon BN, Choi KC, Kim K, Kim TJ, Ham J, Jang HJ, Kang KS and Ko H. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-beta1-induced epithelialmesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance. Toxicology. 2014; 322:23-33.